

JSA Best Presentation Award 2010

Aspirin-Intolerant Asthma (AIA) Assessment Using the Urinary Biomarkers, Leukotriene E₄ (LTE₄) and Prostaglandin D₂ (PGD₂) Metabolites

Noritaka Higashi¹, Masami Taniguchi¹, Haruhisa Mita¹, Hiromichi Yamaguchi¹, Emiko Ono¹ and Kazuo Akiyama¹

ABSTRACT

The clinical syndrome of aspirin-intolerant asthma (AIA) is characterized by aspirin/nonsteroidal anti-inflammatory drug intolerance, bronchial asthma, and chronic rhinosinusitis with nasal polyposis. AIA reactions are evidently triggered by pharmacological effect of cyclooxygenase-1 inhibitors. Urine sampling is a non-invasive research tool for time-course measurements in clinical investigations. The urinary stable metabolite concentration of arachidonic acid products provides a time-integrated estimate of the production of the parent compounds *in vivo*. AIA patients exhibit significantly higher urinary concentrations of leukotriene E₄ (LTE₄) and 1,15-dioxo-9 α -hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor-PGDM), a newly identified metabolite of PGD₂, at baseline. This finding suggests the possibility that increased mast cell activation is involved in the pathophysiology of AIA even in a clinically stable condition. In addition, lower urinary concentrations of primary prostaglandin E₂ and 15-epimer of lipoxin A₄ at baseline in the AIA patients suggest that the impaired anti-inflammatory elements may also contribute to the severe clinical outcome of AIA. During the AIA reaction, the urinary concentrations of LTE₄ and PGD₂ metabolites, including tetranor-PGDM significantly and correlatively increase. It is considered that mast cell activation probably is a pathophysiologic hallmark of AIA. However, despite the fact that cyclooxygenase-1 is the dominant *in vivo* PGD₂ biosynthetic pathway, the precise mechanism underlying the PGD₂ overproduction resulting from the pharmacological effect of cyclooxygenase-1 inhibitors in AIA remains unknown. A comprehensive analysis of the urinary concentration of inflammatory mediators may afford a new research target in elucidating the pathophysiology of AIA.

KEY WORDS

aspirin, asthma, biomarker, cysteinyl-leukotriene, mast cell, prostaglandin D₂, urine

ABBREVIATIONS

AIA, Aspirin-intolerant asthma; NSAID, Nonsteroidal anti-inflammatory drug; CRSwNP, Chronic rhinosinusitis with nasal polyposis; COX, Cyclooxygenase; CysLT, Cysteinyl-leukotriene; PGD₂, Prostaglandin D₂; LTE₄, Leukotriene E₄; HPLC, High-performance liquid chromatography; ATA, Aspirin-tolerant asthma; 15-epi-LXA₄, 15-Epimer of lipoxin A₄; IgE, Immunoglobulin E; LXA₄, Lipoxin A₄; 9 α ,11 β -PGF₂, 9 α ,11 β -Prostaglandin F₂; 2,3-Dinor-9 α ,11 β -PGF₂, 2,3-Dinor-9 α ,11 β -prostaglandin F₂; Tetranor-PGDM, 11,15-Dioxo-9 α -hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid; EIA, Enzyme immunoassay; *ent*-PGF₂ α , Prostaglandin F₂ α enantiomer;

¹Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan.

Conflict of interest: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Correspondence: Noritaka Higashi, MD, PhD, Clinical Research

Center for Allergy and Rheumatology, Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara, Kanagawa 252-0392, Japan.

Email: n-higashi@sagamihara-hosp.gr.jp

Received 22 November 2011. Accepted for publication 7 February 2012.

©2012 Japanese Society of Allergology

GPCR, G-protein coupled receptors; PPAR- γ , Peroxisome proliferator activated receptor γ ; BMMC, Bone marrow-derived mast cell; 15R-PGD₂, 15R-methyl-prostaglandin D₂; DP2, Prostaglandin D₂ receptor 2; GSH, Glutathione.

INTRODUCTION

The clinical syndrome of aspirin-intolerant asthma (AIA) is characterized by aspirin/nonsteroidal anti-inflammatory drug (NSAID) intolerance, bronchial asthma and chronic rhinosinusitis with nasal polypsis (CRSwNP).^{1,2} Aspirin/NSAID-induced asthma reactions are triggered by pharmacological effect of cyclooxygenase-1 (COX-1) inhibitors, whereas COX-2-specific inhibitors (coxibs) are tolerated in the vast majority of cases.^{3,4} Several clinicoepidemiologic studies⁵⁻⁹ have demonstrated that AIA is one of the common risk factors for the development of refractory asthma. Previous *in vitro* studies demonstrated

the release of chemical mediators from leukocytes in AIA patients and these *in vitro* tests may be applicable to a diagnosis of aspirin/NSAIDs intolerance.¹⁰⁻¹³ However, there is no experimental evidence which directly supports this hypothesis.^{14,15} That is, there is neither an appropriate *in vitro* test to diagnose AIA nor an animal model to help fully elucidate the pathogenesis of AIA. Thus, biological fluid samples from AIA subjects are the only research tools available. Urine samples constitute a non-invasive research tool for time-course measurements in the clinical setting, although such data does not provide any information on the sites of the production. The urinary concentration of chemical mediator metabolites is remarkably

Table 1 Inflammatory mediators in biological samples

Invasive							Non-invasive
BALF	ELF	Induced sputum	Plasma	EBC	Saliva	Urine	
unmetabolized compounds			metabolites	unmetabolized compounds		urinary metabolites	
local production			whole body production	Local production		whole body production	
instantaneous measure of endogenous production of the compounds						time-integrated measure of endogenous production of the compounds	
	ext. high levels		ext. Low levels	Low levels		relatively high levels	

Abbreviations: BALF, bronchoalveolar lavage fluid; ELF, epithelial lining fluid; EBC, exhaled breath condensate; ext., extremely.




Fig. 1 Arachidonic acid cascade (Adapted from Yamaguchi *et al.*⁴⁹).




Fig. 2 Changes in the urinary LTE₄ concentrations following endoscopic sinus surgery (ESS). Horizontal bars indicate medians. Patients with aspirin-intolerant asthma (AIA, $n = 19$) and patients with aspirin tolerant asthma (ATA, $n = 8$) are denoted by circles and squares, respectively. Additional urinary data (12 AIA patients, closed circles) were included in the original figure published previously.²⁶ The asterisks (*, **) indicate $p < 0.05$ and $p < 0.01$, respectively, in comparison with baseline values (pre-ESS).

higher than the plasma concentration, which allows us to correlate the mediator metabolite levels with clinical symptoms. The characteristics of the biological fluid samples are shown in Table 1. It is important to note that because various arachidonic acid metabolites (Fig. 1) are rapidly metabolized *in vivo*, the urinary concentration of their stable metabolites provides a time-integrated estimate of the production of the parent compounds, allowing a detection of their generation *in vivo*.¹⁶ In this review article, we focus on the clinical implications of urinary biomarkers such as cysteinyl-leukotrienes (CysLTs) and prostaglandin D₂ (PGD₂) metabolites in AIA.

URINARY LEUKOTRIENE (LT) E₄ IN AIA AT BASELINE

Since the leukotriene (LT) C₄ is easily metabolized in the lungs and/or the liver, and then disappears into the body fluid, LTE₄ is the predominant metabolite among the CysLTs of defined structure.^{17,18} It is reported that 4-13% of the intravenous or inhaled dose of LTC₄ is excreted in the urine.^{16,19,20} Arachidonic acid metabolites are present in extremely small quantities in biological fluids (on an order ranging from pg/ml to ng/ml). When assayed by enzyme immunoassay (EIA), biological samples should be purified in order to eliminate any interfering substances. Thin-layer chromatography has been commonly employed to remove such interfering substances. We believe that purification using high-performance liquid

chromatography (HPLC) is also convenient and provides a suitable quantification procedure. Recently it has been emphasized that additional chromatographic steps are required for obtaining reliable data on the urinary LTE₄ concentrations.^{21,22} There is increasing evidence that the AIA group exhibits a significantly higher urinary LTE₄ excretion level at baseline than the aspirin-tolerant asthma (ATA) group, even in a clinically stable condition.²³⁻³¹ Of late it appears that the baseline urinary LTE₄ concentrations in the AIA group are on a decline compared with original data by Christie *et al.*²³ and Kumlin *et al.*,²⁹ perhaps because of a stabilization of asthma symptoms by inhaled corticosteroids. Considering the distinct evidence from several immunohistochemical studies,³²⁻³⁴ LTC₄ producing cells such as eosinophils and mast cells seem to contribute to increased baseline concentrations of urinary LTE₄ in subjects with AIA. Interestingly, we have demonstrated that a severe ATA group with chronic rhinosinusitis with nasal polyposis (CRSwNP) also exhibited a significantly higher urinary LTE₄ concentration at baseline.²⁶ That is, CysLT overproduction is associated with the clinical features of severe asthma with CRSwNP, that is, the so-called “aspirin triad” in AIA. Taken together with the evidence that there is a close relationship between CRSwNP and CysLT overproduction in asthmatic subjects, we have proposed the concept of “hyper-leukotrienuria”.^{26,35} The preliminary data indicates that aspirin intolerance seldom develops in pa-




Fig. 3 Evidence of clinical improvement of asthma symptoms after endoscopic sinus surgery (ESS). Horizontal bars indicate means. The asterisk (*) indicates $p < 0.05$ in comparison with baseline values (pre-ESS, $n = 9$).

Table 2 Analytical significance of urinary eicosanoid concentrations

Urinary eicosanoids	Metabolites compounds				Unmetabolites compounds	
	LTE ₄	D-ring PGDM	F-ring PGDM	PGEM and tetranor- PGEM	primary PGE ₂	<i>ent</i> -PGF ₂ α
Derived from	5-LO	COX (COX-1 dominant)		COX (COX-2 dominant)		non- enzymatic
As an index of	whole body production				local kidney production	free radical- mediated production
	LTC ₄	PGD ₂		PGE ₂		

Abbreviations: LTE₄, leukotriene E₄; 5-LO, 5-lipoxygenase; PGDM, prostaglandin D₂ metabolite; F-ring PGDM, 9α,11β-prostaglandin F₂ and 2,3-Dinor-9α,11β-prostaglandin F₂; D-ring PGDM, tetranor-PGDM; PGE₂, prostaglandin E₂; PGEM, 13,14-dihydro-15keto-prostaglandin E₂; tetranor-PGEM, 9,15-dioxo-11α-hydroxy-2,3,4,5-tetranor-prostane-1,20-dioic acid; COX, cyclooxygenase; ent-PGF₂α, prostaglandin F₂α enantiomer.

The original table has been published previously with some modification.²⁵

tients with ATA, even with hyper-leukotrienuria, throughout the course of a 5-year follow-up period (unpublished data). This clinical finding leads us to the hypothesis that CysLT overproduction *in vivo* does not promote aspirin intolerance by itself. Interestingly, it was demonstrated for the first time that there is a significant decrease in the urinary LTE₄ concentrations after endoscopic sinus surgery in both the AIA and ATA groups. We carried out further investigation in 12 additional AIA patients, and found further evidence which suggests that CRSwNP is involved in CysLT overproduction in asthmatic subjects, as shown in Figure 2. Furthermore, we have preliminarily determined the clinical improvement in asthma-related emergency room visits and bronchial hyperresponsiveness after endoscopic sinus surgery. Unexpectedly, sinus surgery resulted in significantly fewer asthma-related emergency room visits. In addition, there were significant increases in the Ach-PC₂₀ values after endoscopic sinus surgery. (unpublished data, Fig. 3) These data typically support the concept of “one airway, one disease”.³⁶ Recent research sug-

gests a close relationship between LT biosynthesis and vascular events such as arteriosclerosis.^{37,38} We have reported significantly increased urinary LTE₄ concentrations in patients with acute exacerbated vasculitides.³⁹ It is also reported that the urinary LTE₄ concentration is slightly increased in current smokers⁴⁰ and obese subjects,⁴¹ suggesting that the urinary LTE₄ concentration may be useful as a non-invasive biomarker of oxidative tissue inflammation and related pathophysiologic events.⁴²

URINARY PGs CONCENTRATIONS IN AIA AT BASELINE

Recently we reported that the urinary PGE₂ concentrations at baseline in the AIA group are significantly lower than the ATA group.²⁵ Since PGE₂ in urine is an unmetabolized compound, the primary PGE₂ concentrations in urine have been considered to predominantly reflect local renal production⁴³ (Table 2). Interestingly, lower spontaneous production of PGE₂ has been reported in epithelial cells from nasal polyps⁴⁴ and sinonasal tissue⁴⁵ in subjects with AIA,




Fig. 4 Urinary PGD₂ metabolites following AIA and anaphylaxis reactions. The log-transformed urinary concentrations of PGD₂ metabolites are expressed as medians and interquartile ranges in the AIA ($n = 10$ or 8^{\S}), ATA ($n = 7$) and anaphylaxis ($n = 8$) groups, respectively. \S In the case of tetranor-PGDM concentrations. The urinary tetranor-PGDM, 2,3-dinor-9 α ,11 β -prostaglandin F₂ and 9 α ,11 β -prostaglandin F₂ are denoted by *squares*, *circles* and *triangles*, respectively. The asterisk (*) indicates $p < 0.05$ compared with baseline values. A dagger (†) indicates $p < 0.05$ for the comparison between the AIA and anaphylaxis groups. Urine samples were collected at baseline and following the reactions.

which is associated with diminished COX-2 expression in these tissues.^{46,47} Inhaled PGE₂ protects against both aspirin-induced bronchoconstriction and the massive release of urinary LTE₄,⁴⁸ so a critical deficiency in PGE₂ “braking” has been postulated as one possible mechanism for the AIA reaction. Similarly we have demonstrated a decreased urinary concentration of 15-epimer of lipoxin A₄ (15-epi-LXA₄),⁴⁹ which is also produced by cell-to-cell interaction involving acetylated COX-2 and 5-lipoxygenase.⁵⁰ In allergic airway inflammation, not only LXA₄ but also 15-epi-LXA₄ block both bronchial hyperresponsiveness and pulmonary inflammation induced by eosinophils via the LXA₄ receptor, leading to decreases in the numbers of eosinophils and T-lymphocytes and decreases in the concentrations of interleukin-5, interleukin-13, eotaxin, immunoglobulin E (IgE), PGs, and CysLTs.⁵¹ Thus, it is a plausible explanation that the low COX-2 expression *in vivo* may result in the lower urinary concentrations of anti-inflammatory PGE₂ and 15-epi-LXA₄ at baseline in the AIA group, suggesting the deficiency of additional anti-inflammatory elements in AIA. Since the AIA subjects excreted significantly higher urinary LTE₄ concentration at baseline even in a clinically stable condition,²³⁻²⁹ as described above, an imbalance between the local production of pro-inflammatory CysLTs and anti-inflammatory 15-epi-LXA₄ and PGE₂ at baseline,

may play an important role in development of refractory asthma in AIA. Unexpectedly, urinary lipoxin A₄ (LXA₄) was significantly lower than 15-epi-LXA₄ because 15-epi-LXA₄ shows a two-fold longer half-life *in vivo*,⁵² as calculated by conversion rate of 15-hydroxyprostaglandin dehydrogenase.

URINARY CONCENTRATIONS OF PG METABOLITES IN AIA AT BASELINE

The major urinary metabolites of PGE₂ and PGD₂ are shown in Table 2. Among LTC₄ producing cells such as eosinophils, basophils and mast cells, it is only the mast cells that produce significant quantities of PGD₂ in human.⁵³ Although there is evidence of some PGD₂ formation by eosinophils, platelets, macrophages and certain T lymphocytes, the reported amounts are 100 to 1000 times lower than those produced during IgE dependent activation of mast cells.⁵⁴⁻⁵⁶ So the urinary PGD₂ metabolites are useful biomarkers of mast cell activation.⁵⁵ Although it is indeed also true that tryptase in the biological fluid samples is a mast cell-specific biomarker, it is impossible to detect tryptase in urine. Furthermore, it was reported that serum tryptase concentration was increased in only 6% of the patients who developed anaphylaxis.⁵⁷ Similarly, Bochenek *et al.* demonstrated that there was no change in serum tryptase despite the five-fold increase in plasma 9 α ,11 β -PGF₂ follow-

ing the early phase of allergen-induced airway obstruction.⁵⁸ Thus, we concluded that the determination of the urinary PGD₂ metabolites is more sensitive and practical than serum tryptase for monitoring mast cell activation.⁵⁹ “F-ring” urinary PGD₂ metabolites, 9 α ,11 β -prostaglandin F₂ (9 α ,11 β -PGF₂) and 2,3-dinor-9 α ,11 β -prostaglandin F₂ (2,3-dinor-9 α ,11 β -PGF₂), has been frequently used in the clinical studies.^{25,55,60,61} Recently, Song *et al.* newly identified the most abundant “D-ring” PGD₂ metabolite in urine, 11,15-dioxo-9 α -hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor-PGDM).⁶¹ We also examined the urinary tetranor-PGDM concentration with a newly commercially available enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA). Our data demonstrated that the urinary tetranor-PGDM concentrations were 4.8-fold (median) higher than 2,3-dinor-9 α ,11 β -PGF₂ or 11.7-fold higher than 9 α ,11 β -PGF₂ at baseline.⁶² Interestingly, the urinary concentrations of tetranor-PGDM and LTE₄ at baseline in the AIA group was significantly higher than the anaphylaxis group⁶² (Fig. 4). To our knowledge, this is the first report of a significantly higher baseline concentration of PGD₂ metabolites in urine in AIA patients, except for patients with mastocytosis.⁶³ Thus, the quantification of tetranor-PGDM may be an attractive strategy for further investigation into mast cell activation. This finding is consistent with the previous reports of higher baseline concentration of sputum PGD₂,²⁷ plasma 9 α ,11 β -PGF₂ and serum tryptase in the AIA patients.⁶⁴ Furthermore, it is reported that there was a significant increase in the number of submucosal mast cell in the bronchial biopsy obtained from AIA versus ATA patients.^{65,66} It is important to note that the purification of urine by HPLC is crucial for the precise quantification of tetranor-PGDM. One limitation of this biomarker of tetranor-PGDM is that it is generally unstable when not stored at -80°C. By contrast, there is no significant difference in the major urinary PGE₂ metabolites, 13,14-dihydro-15keto-PGE₂ (PGEM) and 9,15-dioxo-11 α -hydroxy-2,3,4,5-tetranor-prostane-1,20-dioic acid (tetranor-PGEM), at baseline between AIA and ATA groups,⁶⁷ in spite of the fact that COX-2 contributes substantially to the biosynthesis of PGE₂⁶⁸ and that lower COX-2 expression is one of the unique characteristics of AIA.^{46,47} Interestingly, aspirin provocation decreases the urinary concentrations of PGE₂ metabolites in only the ATA group, not the AIA group.⁶⁷

LTE₄ AND PG METABOLITES DURING ASPIRIN/NSAIDS-INTOLERANT ASTHMA REACTION

During systemic aspirin provocation, a runny nose and nasal congestion (>90%) are the first symptoms, and then acute bronchoconstriction develops more than 30 min after the administration of threshold dose of aspirin. This aspirin-induced bronchoconstriction

almost never lasts beyond 24 hours. Extrapulmonary reactions such as skin reactions and gastrointestinal symptoms are minor complications.⁶⁹ The urinary LTE₄ concentrations after the systemic provocation test with aspirin in the AIA group significantly increased above the basal concentrations (approximately a 3-30-fold increase).^{25,28,30,70,71} There is evidence that shows 1) excessive CysLTs overproduction *in vivo* during aspirin-induced bronchoconstriction is a pathophysiologic hallmark of AIA without exception, 2) an increase in urinary LTE₄ concentration after aspirin challenge, the most dramatic event in AIA, correlates with the severity of the aspirin-induced reaction and 3) there is no significant increase in the urinary LTE₄ concentration in ATA patients. Although CysLTs play a key role in the pathophysiology of aspirin/NSAID intolerance, LT receptor antagonists can attenuate but cannot completely block aspirin-induced asthmatic reactions.⁷² One question that needs to be answered is which cells produce CysLTs during provocation test. Our study demonstrated the urinary concentrations of LTE₄ and PGD₂ metabolites (2,3-dinor-9 α ,11 β -PGF₂,²⁵ 9 α ,11 β -PGF₂^{25,28} and tetranor-PGDM⁶²) were significantly increased and correlated with each other after the aspirin provocation test in the AIA group. Bochenek *et al.*⁶⁴ have demonstrated an increase in urinary 9 α ,11 β -PGF₂ and serum tryptase after aspirin provocation in AIA patients. Increased concentrations of histamine and N^ε-methyhistamine, a urinary metabolite of histamine, have also observed after aspirin provocation in AIA patients.^{28,73} Taken together, it is clear that mast cell activation is closely associated with aspirin-induced bronchoconstriction. However, markedly different patterns of CysLTs and PGD₂ release in the aspirin-intolerant asthma group and the IgE-mediated anaphylaxis group,²⁵ respectively, leads us to speculate that there may be other, unknown cellular sources besides mast cells for CysLTs synthesis during acute AIA reactions. Because eosinophils also have the capacity to generate both LTC₄ in large quantity and PGD₂ in much smaller quantity,⁷⁴⁻⁷⁷ eosinophils may be responsible for the production of some of these mediators. Concomitantly with LTC₄, the urinary concentration of LTB₄ glucuronide, a urinary metabolite of LTB₄, increased in the AIA group after aspirin provocation. Thus, there may be a possibility that these mediators were partly generated from eosinophils by cell-to-cell interaction.⁷⁰ However, considering that there was no significant change in the serum level of eosinophil cationic protein,⁷⁸ urinary eosinophil-derived neurotoxin or 3-bromotyrosine,⁷¹ which are biomarkers of eosinophil activation, during AIA acute reaction, this hypothesis of activated eosinophils involvement remains a matter of speculation. More importantly, basophils also may be partly responsible for the production of LTC₄ and histamine, but not PGD₂.^{55,79}

Song *et al.* demonstrated that the urinary tetranor-PGDM concentrations were suppressed by inhibition with aspirin, but not by a selective inhibition of COX-2.⁶¹ Interestingly, Daham *et al.* recently demonstrated that the urinary tetranor-PGDM concentration remains unchanged in both the AIA and ATA groups following the administration of the selective COX-2 inhibitor celecoxib.⁶⁸ Taken together, despite the fact that COX-1 is the dominant *in vivo* PGD₂ biosynthesis pathway, the precise mechanism underlying the PGD₂ overproduction through the pharmacological effect of COX-1 inhibitors in the AIA group remains unknown.

PG PRODUCTION VIA THE FREE RADICAL-MEDIATED "ISOPROSTANE PATHWAY"

Recently, it was reported that there is another pathway in which arachidonic acid is metabolized *in vivo* by a free radical-mediated mechanism to yield a series of PG-like compounds termed isoprostanes that is independent on the catalytic activity of the COX enzyme.⁸⁰ In contrast with COX-derived PGs, which is an optically pure form, the radical-mediated peroxidation of arachidonic acid generates a racemic mixture of PGs (Fig. 5). Thus, the presence of the enantiomer to COX-derived PG indicates that the PG is generated via a free radical-mediated mechanism.⁸¹ The concentration of the PG enantiomer in urine is a reliable index of systemic isoprostane and lipid oxidation.^{81,82} In particular, quantification of the urinary PGF₂α enantiomer (*ent*-PGF₂α) constitutes a valuable tool for assessing oxidant stress *in vivo*.⁸² As judged by the urinary *ent*-PGF₂α concentration, free radical-mediated PG generation is also involved in the pathophysiology of IgE-mediated anaphylaxis.²⁵ Therefore, we hypothesized that a free radical-mediated mechanism might be also responsible for the PGD₂ production which occurs during the AIA reaction. However, unexpectedly, there was no change in the urinary *ent*-PGF₂α concentrations after aspirin provocation in the AIA group.²⁵ It seems that PGD₂ overproduction *in vivo* in the AIA group after the aspirin provocation test is independent of the isoprostane pathway. More interestingly, recent studies on PG biosynthesis have demonstrated that nitric oxide nitrosylates cytosolic phospholipase A₂ (cPLA₂)⁸³ and COX-2,⁸⁴ resulting in the activation of these two enzymes and an increase in PG synthesis. These findings suggest that oxidative stress induces the post-translational modification of enzymes associated with eicosanoid biosynthesis.⁸⁵

CONCLUSION AND CLINICAL RELEVANCE

This review article focuses on clinical significance of urinary biomarkers in AIA. We have analyzed a variety of biological samples, including serum, saliva,^{24,86} sputum,²⁷ exhaled breath condensate^{87,88} and bronchoalveolar lavage fluid^{87,89} to assess the pathophysi-




Fig. 5 Chemical structures of prostaglandin F₂α and *ent*-prostaglandin F₂α.

ology of allergic diseases such as AIA. To our knowledge, the biomarker of urinary LTE₄ is the only appropriately sensitive biomarker for the aspirin-induced asthma/sinus reaction. Christie *et al.*⁹⁰ have reported that AIA subjects exhibit selective hyperresponsiveness to LTE₄, but not to LTC₄, relative to that seen in ATA subjects. Interestingly, P2Y₁₂, the adenosine diphosphate receptor, is responsible for the LTE₄-mediated activation and proliferation of mast cells, as well as amplification of allergic pulmonary inflammation.^{91,92} Taken these findings together, it is suggested that a mechanism underlying AIA is that LTE₄-mediated signaling pathway may play an important role for the development of refractory asthma. In addition, new receptors for LTE₄ have recently been discovered. Their roles in CysLT signaling and related diseases, in particular AIA, need to be elucidated.^{93,94} Single measurements of urinary LTE₄ concentrations do not allow a demonstration of the cellular source and target organ of CysLT production. We preliminarily compared the urinary LTE₄ concentrations in the same patients (*n* = 3) exhibiting the same extent of bronchoconstriction upon systemic challenge and inhalation challenge. The duration between the two different challenges was more than 2 weeks to avoid the refractory period in AIA. The extent of increase in the urinary LTE₄ concentration after systemic aspirin challenge was 3 to 10-fold higher than aspirin inhalation challenge (data not shown). This finding suggests that the site of CysLT production is not only the bronchi and lungs. Therefore, further quantification of the urinary PGD₂ metabolite concentrations are helping to elucidate how

mast cell activation is involved in the pathophysiology of AIA.^{24,25,28,64,95} However, the precise mechanisms underlying the PGD₂ overproduction in the AIA group, which occurred despite the administration of a COX inhibitor, remains unknown. Paruchuri *et al.* have reported that LTE₄ activates human mast cells by a pathway that involves a cooperation between MK571-sensitive G protein coupled receptors (GPCRs) and peroxisome proliferator activated receptor γ (PPAR γ), a nuclear receptor for dietary lipids. LTE₄ possesses a capacity for upregulating COX-2 expression and causing PGD₂ generation.⁹⁶ Furthermore, He *et al.*⁸⁵ have demonstrated that treatment of bone marrow-derived mast cells (BMMC) with PGD₂ reduces the ability of BMMC to generate LTC₄ upon calcium ionophore stimulation, but has little effect on LTB₄ generation. This effect can be reproduced by a selective agonist of the DP₂ receptor, 15R-methyl-PGD₂ (15R-PGD₂). 15R-PGD₂ exerts its suppressive effect via a reduction in intracellular glutathione (GSH), a mechanism that involves the conjugation of its non-enzymatic breakdown product with GSH. Quantification of the new biomarker PGD₂ metabolite tetranor-PGD₂ provides a clinically useful tool for assessing mast cell activation *in vivo*. Urine samples afford a most non-invasive research tool for time-course measurements in a clinical study, and a lipidomics approach using biological fluid samples such as urine will provide further clinical data targeting mast cell activation, not only in allergic diseases, but also infectious diseases and cancer.

ACKNOWLEDGEMENTS

We thank Drs Rikuo Osaki, Yukio Kawagishi (Toyama, Japan) for research collaborators, Mr Keiichi Kajiwar, Mrs Itsuko Ito, and Misuzu Matsumoto (Sagamihara, Japan) for technical and laboratory assistance, Drs Ai Higashi, Maki Hasegawa, Yuji Maeda (Sagamihara, Japan) and Professors Sven-Erik Dahlén, Maria Kummlin (Stochholm, Sweden), Professors Mitsuhiko Osame, Masaharu Kawabata, and Hiromasa Inoue (Kagoshima, Japan) for critical advices for the clinical study. This work was supported by the Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare of Japan. We have won the award of Japanese Society of Allergology in 2010.

REFERENCES

- Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. *Ann Intern Med* 1968;**68**:975-83.
- Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. *J Allergy Clin Immunol* 2006;**118**:773-86; quiz 87-8.
- Gyllfors P, Bochenek G, Overholt J *et al.* Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects

- tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. *J Allergy Clin Immunol* 2003;**111**:1116-21.
- Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. *N Engl J Med* 2001;**344**:142.
- Group TES. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J* 2003;**22**:470-7.
- Moore WC, Bleecker ER, Curran-Everett D *et al.* Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol* 2007;**119**:405-13.
- Dolan CM, Fraher KE, Bleecker ER *et al.* Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. *Ann Allergy Asthma Immunol* 2004;**92**:32-9.
- Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. *Chest* 2007;**132**:1882-9.
- Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. *J Allergy Clin Immunol* 2005;**116**:970-5.
- Williams WR, Pawlowicz A, Davies BH. In vitro tests for the diagnosis of aspirin-sensitive asthma. *J Allergy Clin Immunol* 1990;**86**:445-51.
- Okuda Y, Hattori H, Takashima T *et al.* Basophil histamine release by platelet-activating factor in aspirin-sensitive subjects with asthma. *J Allergy Clin Immunol* 1990;**86**:548-53.
- Czech W, Schöpf E, Kapp A. Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. *Inflamm Res* 1995;**44**:291-5.
- Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance. *Allergy* 1996;**51**:506-10.
- Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szczeklik A. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leucocytes precludes its value for aspirin sensitivity testing in asthma. *Clin Exp Allergy* 2000;**30**:1785-91.
- Bavbek S, Dursun AB, Birben E, Kalayci O, Misirligil Z. Cellular allergen stimulation test with acetylsalicylic acid: lysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity. *Int Arch Allergy Immunol* 2009;**149**:58-64.
- Dworski R, Sheller JR. Urinary mediators and asthma. *Clin Exp Allergy* 1998;**28**:1309-12.
- Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. *Allergy* 1997;**52**:124-35.
- Denzlinger C, Guhlmann A, Scheuber PH, Wilker D, Hammer DK, Keppler D. Metabolism and analysis of cysteinyl leukotrienes in the monkey. *J Biol Chem* 1986;**261**:15601-6.
- Maltby NH, Taylor GW, Ritter JM, Moore K, Fuller RW, Dollery CT. Leukotriene C₄ elimination and metabolism in man. *J Allergy Clin Immunol* 1990;**85**:3-9.

20. Orning L, Kaijser L, Hammarstrom S. In vivo metabolism of leukotriene C₄ in man: urinary excretion of leukotriene E₄. *Biochem Biophys Res Commun* 1985;**130**:214-20.
21. Mita H, Oosaki R, Mizushima Y, Kobayashi M, Akiyama K. Efficient method for the quantitation of urinary leukotriene E₄: extraction using an Empore C18 disk cartridge. *J Chromatogr B Biomed Sci Appl* 1997;**692**:461-6.
22. Armstrong M, Liu AH, Harbeck R, Reisdorph R, Rabinovitch N, Reisdorph N. Leukotriene-E₄ in human urine: Comparison of on-line purification and liquid chromatography-tandem mass spectrometry to affinity purification followed by enzyme immunoassay. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009;**877**:3169-74.
23. Christie PE, Tagari P, Ford-Hutchinson AW *et al*. Urinary leukotriene E₄ concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. *Am Rev Respir Dis* 1991;**143**:1025-9.
24. Gaber F, Daham K, Higashi A *et al*. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. *Thorax* 2008;**63**:1076-82.
25. Higashi N, Mita H, Ono E *et al*. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. *J Allergy Clin Immunol* 2010;**125**:1084-91.e6.
26. Higashi N, Taniguchi M, Mita H *et al*. Clinical features of asthmatic patients with increased urinary leukotriene E₄ excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol* 2004;**113**:277-83.
27. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. *Clin Exp Allergy* 2002;**32**:1484-90.
28. Mita H, Endoh S, Kudoh M *et al*. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. *Allergy* 2001;**56**:1061-7.
29. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E₄ and 11-dehydro-thromboxane B₂ in response to bronchial provocations with allergen, aspirin, leukotriene D₄, and histamine in asthmatics. *Am Rev Respir Dis* 1992;**146**:96-103.
30. Kawagishi Y, Mita H, Taniguchi M *et al*. Leukotriene C₄ synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. *J Allergy Clin Immunol* 2002;**109**:936-42.
31. Oosaki R, Mizushima Y, Mita H, Shida T, Akiyama K, Kobayashi M. Urinary leukotriene E₄ and 11-dehydrothromboxane B₂ in patients with aspirin-sensitive asthma. *Allergy* 1997;**52**:470-3.
32. Sampson AP, Cowburn AS, Sladek K *et al*. Profound overexpression of leukotriene C₄ synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. *Int Arch Allergy Immunol* 1997;**113**:355-7.
33. Cowburn AS, Sladek K, Soja J *et al*. Overexpression of leukotriene C₄ synthase in bronchial biopsies from patients with aspirin-intolerant asthma. *J Clin Invest* 1998;**101**:834-46.
34. Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC₄S-expressing cells in aspirin-tolerant asthma. *Am J Respir Cell Mol Biol* 2003;**29**:683-93.
35. Taniguchi M, Higashi N, Ono E, Mita H, Akiyama K. Hyperleukotrieneuria in patients with allergic and inflammatory disease. *Allergol Int* 2008;**57**:313-20.
36. Bousquet J, Reid J, van Weel C *et al*. Allergic rhinitis management pocket reference 2008. *Allergy* 2008;**63**:990-6.
37. Back M. Leukotriene signaling in atherosclerosis and ischemia. *Cardiovasc Drugs Ther* 2009;**23**:41-8.
38. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. *Circulation* 1992;**85**:230-6.
39. Higashi N, Mita H, Taniguchi M *et al*. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. *J Allergy Clin Immunol* 2004;**114**:1353-8.
40. Fauler J, Frolich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. *Eur J Clin Invest* 1997;**27**:43-7.
41. Stanke-Labesque F, Bäck M, Lefebvre B *et al*. Increased urinary leukotriene E₄ excretion in obstructive sleep apnea: effects of obesity and hypoxia. *J Allergy Clin Immunol* 2009;**124**:364-70, 70.e1-2.
42. Wu X, Cai H, Xiang YB *et al*. Intra-person variation of urinary biomarkers of oxidative stress and inflammation. *Cancer Epidemiol Biomarkers Prev* 2010;**19**:947-52.
43. Frolich JC, Wilson TW, Sweetman BJ *et al*. Urinary prostaglandins. Identification and origin. *J Clin Invest* 1975;**55**:763-70.
44. Kowalski ML, Pawliczak R, Wozniak J *et al*. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. *Am J Respir Crit Care Med* 2000;**161**:391-8.
45. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. *J Allergy Clin Immunol* 2005;**115**:1189-96.
46. Picado C, Fernandez-Morata JC, Juan M *et al*. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. *Am J Respir Crit Care Med* 1999;**160**:291-6.
47. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. *J Allergy Clin Immunol* 2004;**114**:814-9.
48. Sestini P, Armetti L, Gambaro G *et al*. Inhaled PGE₂ prevents aspirin-induced bronchoconstriction and urinary LTE₄ excretion in aspirin-sensitive asthma. *Am J Respir Crit Care Med* 1996;**153**:572-5.
49. Yamaguchi H, Higashi N, Mita H *et al*. Urinary concentrations of 15-epimer of lipoxin A₄ are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. *Clin Exp Allergy* 2011;**41**:1711-8.
50. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. *Prostaglandins Other Lipid Mediat* 2002;**68-69**:433-55.
51. Levy BD, De Sanctis GT, Devchand PR *et al*. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A₄. *Nat Med* 2002;**8**:1018-23.
52. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN. Oxidoreductases in lipoxin A₄ metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B₄ 12-hydroxydehydrogenase in inflammation. *J Biol Chem* 2000;**275**:25372-80.
53. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ 2nd. Prostaglandin D₂ generation after activation of rat and human mast cells with anti-IgE. *J Immunol* 1982;**129**:1627-31.
54. Kanaoka Y, Urade Y. Hematopoietic prostaglandin D synthase. *Prostaglandins Leukot Essent Fatty Acids* 2003;**69**:

- 163-7.
55. Dahlen SE, Kumlin M. Monitoring mast cell activation by prostaglandin D2 in vivo. *Thorax* 2004;**59**:453-5.
 56. O'Sullivan S. On the role of PGD2 metabolites as markers of mast cell activation in asthma. *Acta Physiol Scand Suppl* 1999;**644**:1-74.
 57. Treudler R, Kozovska Y, Simon JC. Severe immediate type hypersensitivity reactions in 105 German adults: when to diagnose anaphylaxis. *J Invest Allergol Clin Immunol* 2008;**18**:52-8.
 58. Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. *Thorax* 2004;**59**:459-64.
 59. Ono E, Taniguchi M, Mita H *et al*. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. *Clin Exp Allergy* 2009;**39**:72-80.
 60. O'Sullivan S, Mueller MJ, Dahlen SE, Kumlin M. Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometry. *Prostaglandins Other Lipid Mediat* 1999;**57**:149-65.
 61. Song WL, Wang M, Ricciotti E *et al*. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. *J Biol Chem* 2008;**283**:1179-88.
 62. Higashi N, Mita H, Yamaguchi H, Fukutomi Y, Akiyama K, Taniguchi M. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. *J Allergy Clin Immunol* 2012;**129**:557-9.
 63. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ 2nd. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. *J Invest Dermatol* 1995;**104**:937-40.
 64. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. *J Allergy Clin Immunol* 2003;**111**:743-9.
 65. Nasser SM, Pfister R, Christie PE *et al*. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. *Am J Respir Crit Care Med* 1996;**153**:90-6.
 66. Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. *Am J Respir Crit Care Med* 1997;**156**:1384-9.
 67. Mastalerz L, Sanak M, Gawlewicz-Mroccka A, Gielicz A, Cmiel A, Szczeklik A. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. *Thorax* 2008;**63**:27-34.
 68. Daham K, Song WL, Lawson JA *et al*. Effects of celecoxib on major prostaglandins in asthma. *Clin Exp Allergy* 2011;**41**:36-45.
 69. Taniguchi M. [Measurement of airway hyperresponsiveness and aspirin sensitivity]. *Arerugi* 2009;**58**:87-96 (in Japanese).
 70. Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K. Increase in urinary leukotriene B glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. *Clin Exp Allergy* 2004;**34**:1262-9.
 71. Mita H, Higashi N, Taniguchi M, Higashi A, Kawagishi Y, Akiyama K. Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge. *Clin Exp Allergy* 2004;**34**:931-8.
 72. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. *Ann Allergy Asthma Immunol* 2000;**85**:477-82.
 73. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. *Am Rev Respir Dis* 1988;**137**:847-54.
 74. Kroegel C, Matthys H. Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. *Immunology* 1993;**78**:279-85.
 75. Parsons WG 3rd, Roberts LJ 2nd. Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils. A potential mast cell-eosinophil interaction. *J Immunol* 1988;**141**:2413-9.
 76. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. *Proc Natl Acad Sci U S A* 1983;**80**:7626-30.
 77. Luna-Gomes T, Magalhaes KG, Mesquita-Santos FP *et al*. Eosinophils as a novel cell source of prostaglandin d2: autocrine role in allergic inflammation. *J Immunol* 2011;**187**:6518-26.
 78. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. *Eur Respir J* 1993;**6**:391-9.
 79. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol* 2012;**125**:S73-80.
 80. Awad JA, Morrow JD, Takahashi K, Roberts LJ 2nd. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. *J Biol Chem* 1993;**268**:4161-9.
 81. Gao L, Zackert WE, Hasford JJ *et al*. Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. *J Biol Chem* 2003;**278**:28479-89.
 82. Yin H, Gao L, Tai HH, Murphey LJ, Porter NA, Morrow JD. Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. *J Biol Chem* 2007;**282**:329-36.
 83. Xu L, Han C, Lim K, Wu T. Activation of cytosolic phospholipase A2alpha through nitric oxide-induced S-nitrosylation. Involvement of inducible nitric-oxide synthase and cyclooxygenase-2. *J Biol Chem* 2008;**283**:3077-87.
 84. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. *Science* 2005;**310**:1966-70.
 85. He P, Laidlaw T, Maekawa A, Kanaoka Y, Xu K, Lam BK. Oxidative stress suppresses cysteinyl leukotriene generation by mouse bone marrow-derived mast cells. *J Biol Chem* 2011;**286**:8277-86.
 86. Ono E, Taniguchi M, Higashi N *et al*. Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma. *Allergol Int* 2011;**60**:37-43.
 87. Ono E, Mita H, Taniguchi M *et al*. Comparison of cysteinyl leukotriene concentrations between exhaled breath condensate and bronchoalveolar lavage fluid. *Clin Exp Al-*

- ergy* 2008;**38**:1866-74.
88. Ono E, Mita H, Taniguchi M *et al.* Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. *J Allergy Clin Immunol* 2008;**122**:768-73.e1.
89. Ono E, Mita H, Taniguchi M *et al.* Concentration of 14,15-leukotriene C₄ (eoxin C₄) in bronchoalveolar lavage fluid. *Clin Exp Allergy* 2009;**39**:1348-52.
90. Christie PE, Schmitz-Schumann M, Spur BW, Lee TH. Airway responsiveness to leukotriene C₄ (LTC₄), leukotriene E₄ (LTE₄) and histamine in aspirin-sensitive asthmatic subjects. *Eur Respir J* 1993;**6**:1468-73.
91. Feng C, Mery AG, Beller EM, Favot C, Boyce JA. Adenine nucleotides inhibit cytokine generation by human mast cells through a Gs-coupled receptor. *J Immunol* 2004;**173**:7539-47.
92. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y₁₂ receptors by in silico and in vitro methods. *Biochem Biophys Res Commun* 2005;**337**:281-8.
93. Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E₄ in mice lacking the cysteinyl leukotriene 1 and 2 receptors. *Proc Natl Acad Sci U S A* 2008;**105**:16695-700.
94. Paruchuri S, Tashimo H, Feng C *et al.* Leukotriene E₄-induced pulmonary inflammation is mediated by the P2Y₁₂ receptor. *J Exp Med* 2009;**206**:2543-55.
95. O'Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D₂ metabolite 9 alpha, 11 beta-prostaglandin F₂ after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. *J Allergy Clin Immunol* 1996;**98**:421-32.
96. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E₄ activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D₂ generation by human mast cells. *J Biol Chem* 2008;**283**:16477-87.